Eli Lilly posts Q3 2026 beat, lifts FY 2026 revenue outlook to $91‑$92 B, trims EPS guidance to $35‑$36
Eli Lilly reported third‑quarter 2026 revenue of $24.4 billion, a 39% year‑over‑year increase, and GAAP earnings of $7.22 per share. Non‑GAAP earnings were $7.48 per share, beating consensus estimates. The company raised its full‑year 2026 revenue guidance to $91 billion‑$92 billion while lowering its adjusted EPS outlook to $35‑$36 per share, citing $4.57 per share of acquired‑in‑process R&D charges from recent acquisitions.



